文献速递前列腺癌

肥胖与临床局限性前列腺癌生化复发:86,490例患者的系统综述与Meta分析

Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-01-06

该系统综述与Meta分析纳入46项队列研究、86,490例临床局限性前列腺癌患者,评估肥胖(BMI≥30 kg/m2)与生化复发(BCR)的关联。肥胖与BCR相关(HR 1.25,95%CI 1.11-1.39,I2=70.3%),BMI每增加5 kg/m2 BCR增加10%(95%CI 4-15%,I2=66.3%)。该关联在接受根治性前列腺切除术的患者中一致,但在接受其他治疗的患者中不一致。

要点

  • 肥胖(BMI≥30 kg/m2)与临床局限性前列腺癌生化复发相关,HR 1.25(95%CI 1.11-1.39)。
  • BMI每增加5 kg/m2,生化复发增加10%(95%CI 4-15%)。
  • 该关联在接受根治性前列腺切除术的患者中一致,其他治疗患者中不一致。

核心结论

  • 肥胖与根治性前列腺切除术后生化复发呈中度、一致的关联。
  • BMI与生化复发的测量方式存在差异,凸显制定标准化临床指南的必要性。
  • 预防性体重控制项目可能对减少临床局限性前列腺癌患者的生化复发有作用。

研究设计与样本

  • 系统综述与随机效应Meta分析,检索PubMed、Web of Science和Scopus自建库至2021年6月1日的文献。
  • 纳入按体重指数(BMI)分层报告生化复发(BCR)的队列研究,共46项队列研究、86,490例前列腺癌患者。
  • 采用纽卡斯尔-渥太华量表(NOS)评估研究质量,比较肥胖患者(BMI≥30 kg/m2)与正常体重者(BMI<25)的BCR风险,并计算BMI每5 kg/m2的连续关联。
  • 进行亚组分析探讨异质性原因,并正式评估因果标准。

主要发现

  • 共14,719例(17.1%)患者发生生化复发。
  • BCR缺乏统一定义。
  • 肥胖与BCR相关(HR 1.25,95%CI 1.11-1.39,I2=70.3%)。
  • BMI每增加5 kg/m2,BCR增加10%(95%CI 4-15%,I2=66.3%)。
  • 异质性较高,但在NOS评分最高质量的亚组及由研究人员测量BMI时异质性降低(I2=0.0%);该关联在接受根治性前列腺切除术的患者中一致,但在接受其他治疗的患者中不一致。

关键数值与推荐

  • 肥胖定义为BMI≥30 kg/m2,正常体重定义为BMI<25。
  • 肥胖与BCR关联的HR为1.25(95%CI 1.11-1.39,I2=70.3%)。
  • BMI每增加5 kg/m2,BCR增加的百分比为10%(95%CI 4-15%,I2=66.3%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • BCR缺乏统一定义。
  • BMI与BCR的测量方式存在差异。
  • 异质性较高(I2=70.3%;BMI每5 kg/m2分析I2=66.3%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association of obesity with biochemical recurrence (BCR) after treatment of clinically localised prostate cancer (PC) shows inconsistent results. Our aim was to systematically review all evidence evaluating obesity as a prognostic factor for BCR. METHODS: We searched PubMed, Web of Science and Scopus, from inception to June 1, 2021. Cohort studies reporting BCR among PC patients stratified by body mass index (BMI) were included. To assess the quality of the selected studies, we used the Newcastle-Ottawa scale (NOS). Risk of BCR among obese patients (BMI ≥ 30 kg/m2) was compared with normal weight (BMI < 25), pooling individual hazard ratios (HR) in random-effect meta-analysis. Associations for continuous BMI per 5 kg/m2 were also calculated. Subgroup analyses were conducted to assess reasons for heterogeneity and causal criteria were formally evaluated. RESULTS: We identified 46 cohort studies including 86,490 PC patients. A total of 14,719 (17.1%) patients developed BCR. There was no consistent definition of BCR. Obesity was associated with BCR (HR: 1.25, 95% CI: 1.11-1.39, I2: 70.3%), and there was a 10% increase (95% CI: 4-15%, I2: 66.3%) in BCR per 5 kg/m2 increase in BMI. The heterogeneity was high but decreased in the subgroup of highest-quality NOS score and when the BMI was measured by the researchers (I2: 0.0%). The association was consistent in patients receiving radical prostatectomy but not in patients receiving other therapies. CONCLUSIONS: Obesity showed a moderate, consistent relationship with biochemical recurrence after radical prostatectomy. Measurement of BMI and BCR was variable, highlighting the need for standardised clinical guidelines. Preventive weight control programs may have a role in reducing BCR for clinically localised PC patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Rivera-Izquierdo M, Pérez de Rojas J, Martínez-Ruiz V, et al. Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients. Prostate Cancer Prostatic Dis. 2022. PMID: 34987170. doi:10.1038/s41391-021-00481-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。